| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/12/2002 | US20020128255 Substituted hydroxyl amine derivatives; inhibitors of beta-secretase, inhibit beta-secretase-mediated cleavage, inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques |
| 09/12/2002 | US20020128247 Phenyl sulfamide derivatives as dietetics, antidiabetics, and hypotensive agents |
| 09/12/2002 | US20020128246 Regulation of intracellular glucocorticoid concentrations |
| 09/12/2002 | US20020128245 Using a 11 beta-reductase inhibitor in the manufacture of a medicament for control of 11-keto steroid conversion to 11 beta-hydroxysteroid in vivo |
| 09/12/2002 | US20020128244 Regulation of intracellular glucocorticoid concentrations |
| 09/12/2002 | US20020128236 Substituted fused pyrroleoximes and fused pyrazoleoximes |
| 09/12/2002 | US20020128223 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 09/12/2002 | US20020128193 Retro-inverso prosaposin-derived peptides and use thereof |
| 09/12/2002 | US20020128183 Gene regulation therapy involving ferritin |
| 09/12/2002 | US20020128173 Method of treating or preventing migraine headaches |
| 09/12/2002 | US20020127715 Adjusting gene expression in preferential cells; obtain pluripotent cells, transform, monitor gene expression, compare to control, detect adjustment in gene expression |
| 09/12/2002 | US20020127694 2786, a novel human aminopeptidase |
| 09/12/2002 | US20020127692 Enzymatic polypeptide for use in the treatment of viral infections, cancer, inflammation, brain disorders and asthma |
| 09/12/2002 | US20020127676 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127644 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 09/12/2002 | US20020127605 Cyclophilin compound for use in the treatment of infections, nervous system, skin, ischemic and vision disorders |
| 09/12/2002 | US20020127558 Genetic polymorphism of MxA protein and use thereof |
| 09/12/2002 | US20020127540 Detecting modulators of bone morphogenic activities; obtain cells, incubate with modulator, monitor expression of reporter molecules, compare to control |
| 09/12/2002 | US20020127290 Contacting cell with Cimicifuga extract for reducing level of amyloid beta polypeptide in or secreted from cell and and monitoring level of amyloid beta polypeptide in or secreted from cell |
| 09/12/2002 | US20020127247 Modified clostridial neurotoxins with altered biological persistence |
| 09/12/2002 | US20020127221 Urocortin proteins and uses thereof |
| 09/12/2002 | US20020127217 A polynucleotides which identify and encode Phosphatidylinositol 4,5-bisphosphate 5-phosphatase (polypeptide) |
| 09/12/2002 | US20020127198 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | CA2442524A1 Matrix stabilized enzyme crystals and methods of use |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440161A1 Inhibitor of monoamine uptake |
| 09/12/2002 | CA2440104A1 New asymmetric process for the preparation of diarylmethylpiperazines derivatives and novel asymmetric diarylmetylamines as intermediates |
| 09/12/2002 | CA2440070A1 Pharmaceutical composition made of cannabis extracts |
| 09/12/2002 | CA2440038A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439939A1 Novel aminodicarboxylic acid derivatives |
| 09/12/2002 | CA2439934A1 Use of protein histidine phosphatase |
| 09/12/2002 | CA2439917A1 Compositions having improved bioavailability of eletriptan |
| 09/12/2002 | CA2439859A1 N-but-3-enyl norbuprenorphine and its use as analgesic |
| 09/12/2002 | CA2439854A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 09/12/2002 | CA2439779A1 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 09/12/2002 | CA2439691A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439647A1 Side-chain-halogenated aminodicarboxylic acid derivatives as medicaments for treatment of cardiovascular disorders |
| 09/12/2002 | CA2439644A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439581A1 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438815A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives |
| 09/12/2002 | CA2438737A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2435277A1 Chimeric polypeptides of serum albumin and uses related thereto |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2432280A1 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1239033A1 Semaphorin receptor |
| 09/11/2002 | EP1238978A2 Intermediates for the synthesis of radiolabelled tropanes |
| 09/11/2002 | EP1238676A1 Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis |
| 09/11/2002 | EP1238668A1 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238059A2 Long-term cell culture compositions and genetically modified animals derived therefrom |
| 09/11/2002 | EP1237930A2 Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization |
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237898A2 N?6 heterocyclic 8-modified adenosine derivatives |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237890A1 Synthesis and methods of use of 9-substituted guanine derivatives |
| 09/11/2002 | EP1237888A2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 09/11/2002 | EP1237887A1 9-(piperazinylalkyl)carbazoles as bax-modulators |
| 09/11/2002 | EP1237886A1 Heterocyclic derivatives |
| 09/11/2002 | EP1237880A2 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 09/11/2002 | EP1237878A2 4-pyrimidinyl-n-acyl-l-phenylalanines |
| 09/11/2002 | EP1237876A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 09/11/2002 | EP1237874A2 Selective neurokinin antagonists |
| 09/11/2002 | EP1237869A1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 09/11/2002 | EP1237851A2 SALTS OF i Cis /i -4-CYANO-4- 3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID |
| 09/11/2002 | EP1237577A2 Transmucosal composition containing a phosphodiesterase inhibitor for the treatment of erectile dysfunction |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237567A2 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 09/11/2002 | EP1237566A2 Intraspinal compositions containing botulinum toxin for treating pain |
| 09/11/2002 | EP1237565A1 Betaglycan as an inhibin receptor and uses thereof |
| 09/11/2002 | EP1237554A2 Use of sodium channel antagonists for the treatment of diseases related to apoptosis |
| 09/11/2002 | EP1237553A2 The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist |
| 09/11/2002 | EP1237552A1 Combination of an ergoline and riluzole for preventing and treating motor neuron diseases |
| 09/11/2002 | EP1237551A1 Pharmaceutical formulations containing zolmitriptan |
| 09/11/2002 | EP1237550A2 Methods for treating cell death diseases and inflammation |
| 09/11/2002 | EP1237548A1 Il-8 receptor antagonists |
| 09/11/2002 | EP1237547A2 Compounds for inhibiting diseases and preparing cells for transplantation |
| 09/11/2002 | EP1237546A2 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 09/11/2002 | EP1237544A1 System and method for extended delivery of a therapeutic agent with its receptor loading dose |
| 09/11/2002 | EP1237539A1 Oral solution containing galanthamine and a sweetening agent |
| 09/11/2002 | EP1237524A2 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 09/11/2002 | EP1047409B1 Tts containing an antioxidant |
| 09/11/2002 | EP0910399B1 Stable pharmaceutical composition of bdnf |